SCHEMBL5409128

SCHEMBL5409128

CCN(CC)c1cc(C)nc2cc(-c3cccc(N)c3)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.41
CRHR1 P34998 4/20 0.41
NOS3 P29474 2/20 0.41
NOS1 P29475 2/20 0.41
NOS2 P35228 2/20 0.41
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
PKM P14618 1/20 0.40
GFER P55789 1/20 0.40
PDPK1 O15530 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.38
NQO2 P16083 3/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5419165 0.81 CRHR1 (0.42) CRHR1KDM4EALDH1A1SMN1; SMN2PDPK1
SCHEMBL27550360 0.79 LATS1 (0.39) CRHR1NOS3NOS1NOS2
SCHEMBL6607044 0.79 NQO2 (0.52) CRHR1KDM4ENPC1ALDH1A1RAB9A
SCHEMBL5400443 0.76 PGR (0.44) CRHR1NPC1MAPTRAB9A
SCHEMBL7140857 0.76 NOS1 (0.37) CRHR1NOS3NOS1NOS2
SCHEMBL27525081 0.74 NOS3 (0.39) MAP4K4NOS3NOS1NOS2SMN1; SMN2
SCHEMBL5420608 0.74 CRHR1 (0.44) CRHR1
SCHEMBL27550359 0.73 PTGS2 (0.36) CRHR1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL14359489 0.71 NPSR1 (0.48) CRHR1KDM4ENPC1ALDH1A1HPGD
SCHEMBL5406751 0.71 NCF1 (0.58) KDM4EALDH1A1MAPTSMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265125-B2 Neuropeptide Y antagonists HOFFMANN-LA ROCHE INC. (US) 2007-09-04 US disclosed
CN-1274676-C Quinoline and quinazoline derivatives HOFFMANN LA ROCHE (CH) 2006-09-13 CN disclosed
US-20050176698-A1 Neuropeptide Y antagonists BREU VOLKER (DE) 2005-08-11 US disclosed
US-6900226-B2 Neuropeptide Y antagonists HOFFMAN-LA ROCHE INC. (US) 2005-05-31 US disclosed
CN-1444563-A Quinoline and quinazoline derivatives HOFFMANN LA ROCHE (CH) 2003-09-24 CN disclosed
EP-1318981-A2 QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2003-06-18 EP disclosed
US-20020052356-A1 Neuropeptide Y antagonists F.HOFFMANN-LA ROCHE AG (CH) 2002-05-02 US disclosed
WO-2002020488-A2 QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176698-A1 Neuropeptide Y antagonists NPY5R, NPY4R, NPY2R MAP4K4 1494/4885CRHR1 76/4885NOS3 604/4885
US-20020052356-A1 Neuropeptide Y antagonists NPY5R, NPY4R, NPY2R MAP4K4 1494/4885CRHR1 76/4885NOS3 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.